Searched for
LUPIN US BUSINESS
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Lupin shares gain 3%, up for second straight session. Here’s whyLupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hi...
- Lupin shares in focus after $250 million U.S. facility plan; Citi retains buy callLupin plans a significant $250 million investment over five years to establish a new manufacturing facility in Coral Springs, Florida. This...
- Just coming to our own in India; confident of growing our US business in next fiscal year: Lupin managementLupin's margin guidance remains around 19.5-20.5%. The company attributes its success to the pivot to complex products, cost-led initiative...
- Lupin appoints Spiro Gavaris as president of US generics bizSpiro, who had most recently served as president of Specialty Generics business at Mallinckrodt Pharmaceuticals and the president of US Inj...
- Lupin to launch nearly 30 products in US market in FY18The drug firm is banking on the introduction of complex generics and biosimilars in the US to maintain its top five position in the market.
- Lupin hire Nicholas Hart to head US businessHis past experiences include Business Unit Head for Reproductive Health at Ferring Pharmaceuticals, Inc and Senior Vice President of Sales ...
- Lupin's US arm takes over Symbiomix TherapeuticsLupin had entered into an arrangement to acquire the company earlier this year.
- Buy Lupin, target Rs 2510: UBSThe global investment bank is of the view that in-licensing deals are likely to drive the Indian business.
- Lupin on buying spree; to acquire German company Temmler Pharma's product portfolioA day after announcing its biggest acquisition deal of $880 million, Lupin today said it will buy Germany-based Temmler Pharma's specialty ...
- US Generic launches are key to Lupin growthLupin's revenue grew 5% yearon-year to Rs 3,144.9 crore during the December 2014 quarter, much lower than the analysts' expectation of 12-1...
- Lupin Pharma's India business a cause for concernLupin Pharma’s underperformance in the domestic market may rein in investors’ bullish stance on the share — a hitherto darling of the India...
- Lupin Q2 net profit up 40% at Rs 406 croreLupin had posted net profit of Rs 290.5 crore in July- September quarter of the previous fiscal, 2012-13.
- Oral Contraceptives Booster to Lupin's US businessAs per the IMS data, the total sales for branded and generic sales for the product stood at $ 361 million for the year ended December 2012.
- Local manufacturing can boost margins for LupinFor a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...
Load More
